HR 10-Q Quarterly Report June 30, 2020

HEALTHCARE REALTY TRUST INC

10-Ks and 10-Qs

10-Q	Quarter ended March 31, 2022
10-K	Fiscal year ended Dec. 31, 2021
10-Q	Quarter ended Sept. 30, 2021
10-Q	Quarter ended June 30, 2021
10-Q	Quarter ended March 31, 2021
10-K	Fiscal year ended Dec. 31, 2020
10-Q	Quarter ended Sept. 30, 2020
10-Q	Quarter ended June 30, 2020
10-Q	Quarter ended March 31, 2020
10-K	Fiscal year ended Dec. 31, 2019
10-Q	Quarter ended Sept. 30, 2019
10-Q	Quarter ended June 30, 2019
10-Q	Quarter ended March 31, 2019
10-K	Fiscal year ended Dec. 31, 2018
10-Q	Quarter ended Sept. 30, 2018
10-Q	Quarter ended June 30, 2018
10-Q	Quarter ended March 31, 2018
10-K	Fiscal year ended Dec. 31, 2017
10-Q	Quarter ended Sept. 30, 2017
10-Q	Quarter ended June 30, 2017
10-Q	Quarter ended March 31, 2017
10-K	Fiscal year ended Dec. 31, 2016
10-Q	Quarter ended Sept. 30, 2016
10-Q	Quarter ended June 30, 2016
10-Q	Quarter ended March 31, 2016
10-K	Fiscal year ended Dec. 31, 2015
10-Q	Quarter ended Sept. 30, 2015
10-Q	Quarter ended June 30, 2015
10-Q	Quarter ended March 31, 2015
10-K	Fiscal year ended Dec. 31, 2014
10-Q	Quarter ended Sept. 30, 2014
10-Q	Quarter ended June 30, 2014
10-Q	Quarter ended March 31, 2014
10-K	Fiscal year ended Dec. 31, 2013
10-Q	Quarter ended Sept. 30, 2013
10-Q	Quarter ended June 30, 2013
10-Q	Quarter ended March 31, 2013
10-K	Fiscal year ended Dec. 31, 2012
10-Q	Quarter ended Sept. 30, 2012
10-Q	Quarter ended June 30, 2012
10-Q	Quarter ended March 31, 2012
10-K	Fiscal year ended Dec. 31, 2011
10-Q	Quarter ended Sept. 30, 2011
10-Q	Quarter ended June 30, 2011
10-Q	Quarter ended March 31, 2011
10-K	Fiscal year ended Dec. 31, 2010
10-Q	Quarter ended Sept. 30, 2010
10-Q	Quarter ended June 30, 2010
10-Q	Quarter ended March 31, 2010
10-K	Fiscal year ended Dec. 31, 2009

PROXIES

DEF 14A	Filed on March 25, 2022
DEF 14A	Filed on March 24, 2021
DEF 14A	Filed on March 25, 2020
DEF 14A	Filed on March 29, 2019
DEF 14A	Filed on March 26, 2018
DEF 14A	Filed on March 21, 2017
DEF 14A	Filed on March 28, 2016
DEF 14A	Filed on March 30, 2015
DEF 14A	Filed on March 27, 2014
DEF 14A	Filed on March 28, 2013
DEF 14A	Filed on March 30, 2012
DEF 14A	Filed on March 30, 2011
DEF 14A	Filed on March 31, 2010

Document

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________

FORM 10-Q



(Mark One)
☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2020
OR
☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to For the transition period to

Commission File Number: 001-11852

HEALTHCARE REALTY TRUST INCORPORATED

(Exact name of Registrant as specified in its charter)



Maryland	62-1507028
(State or other jurisdiction of Incorporation or organization)	(I.R.S. Employer Identification No.)

3310 West End Avenue, Suite 700

Nashville , Tennessee 37203

(Address of principal executive offices)

( 615 ) 269-8175

(Registrant's telephone number, including area code)

Securities Registered Pursuant to Section 12(b) of the Act:



Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common stock, $0.01 par value per share	HR	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

Large accelerated filer ☒ Accelerated filer ☐

Non-accelerated filer ☐ Smaller reporting company ☐

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for

complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of July 31, 2020 , the Registrant had 136,048,233 shares of Common Stock outstanding.

HEALTHCARE REALTY TRUST INCORPORATED

FORM 10-Q

June 30, 2020

Table of Contents



PART I - FINANCIAL INFORMATION
Item 1	Financial Statements	1
	Condensed Consolidated Balance Sheets	1
	Condensed Consolidated Statements of Income	2
	Condensed Consolidated Statements of Comprehensive Income	3
	Condensed Consolidated Statements of Equity	4
	Condensed Consolidated Statements of Cash Flows	6
	Notes to the Condensed Consolidated Financial Statements	7
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3	Quantitative and Qualitative Disclosures about Market Risk	32
Item 4	Controls and Procedures	32

PART II - OTHER INFORMATION
Item 1	Legal Proceedings	33
Item 1A	Risk Factors	33
Item 2	Unregistered Sales of Equity and Use of Proceeds	36
Item 6	Exhibits	36

SIGNATURE		38

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Healthcare Realty Trust Incorporated

Condensed Consolidated Balance Sheets

Amounts in thousands, except per share data



ASSETS
	Unaudited JUNE 30, 2020			DECEMBER 31, 2019
Real estate properties
Land	$	312,139		$	289,751
Buildings, improvements and lease intangibles	3,937,657			3,986,326
Personal property	10,849			10,538
Construction in progress	—			48,731
Land held for development	24,647			24,647
Total real estate properties	4,285,292			4,359,993
Less accumulated depreciation and amortization	( 1,169,298		)	( 1,121,102		)
Total real estate properties, net	3,115,994			3,238,891
Cash and cash equivalents	43,680			657
Assets held for sale, net	—			37
Operating lease right-of-use assets	124,398			126,177
Financing lease right-of-use assets	19,884			12,667
Net investment in sales-type leases	244,381			—
Other assets, net	183,616			185,426
Total assets	$	3,731,953		$	3,563,855

LIABILITIES AND STOCKHOLDERS' EQUITY
Liabilities
Notes and bonds payable	$	1,554,936		$	1,414,069
Accounts payable and accrued liabilities	65,485			78,517
Liabilities of properties held for sale	—			145
Operating lease liabilities	91,259			91,574
Financing lease liabilities	18,595			18,037
Other liabilities	72,317			61,504
Total liabilities	1,802,592			1,663,846
Commitments and contingencies
Stockholders' equity
Preferred stock, $.01 par value per share; 50,000 shares authorized; none issued and outstanding	—			—
Common stock, $.01 par value per share; 300,000 shares authorized; 136,048 and 134,706 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively	1,360			1,347
Additional paid-in capital	3,529,559			3,485,003
Accumulated other comprehensive loss	( 20,294		)	( 6,175		)
Cumulative net income attributable to common stockholders	1,207,132			1,127,304
Cumulative dividends	( 2,788,396		)	( 2,707,470		)
Total stockholders' equity	1,929,361			1,900,009
Total liabilities and stockholders' equity	$	3,731,953		$	3,563,855

The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 , are an integral part of these financial statements.

Table of Contents

Healthcare Realty Trust Incorporated

Condensed Consolidated Statements of Income

For the Three and Six Months Ended June 30, 2020 and 2019

Amounts in thousands, except per share data

Unaudited



	THREE MONTHS ENDED June 30,						SIX MONTHS ENDED June 30,
	2020			2019			2020			2019
Revenues
Rental income	$	122,358		$	114,351		$	245,001		$	225,046
Other operating	1,332			1,966			3,496			3,928
	123,690			116,317			248,497			228,974
Expenses
Property operating	46,580			44,286			96,134			87,012
General and administrative	7,434			7,845			16,199			16,355
Acquisition and pursuit costs	431			422			1,181			726
Depreciation and amortization	47,691			43,926			95,188			86,588
	102,136			96,479			208,702			190,681
Other Income (Expense)
Gain on sales of real estate assets	68,267			4,849			68,218			4,865
Interest expense	( 14,442		)	( 13,850		)	( 28,402		)	( 27,438		)
Impairment of real estate assets	—			( 5,610		)	—			( 5,610		)
Interest and other income (expense), net	134			( 743		)	217			( 735		)
	53,959			( 15,354		)	40,033			( 28,918		)
Net Income	$	75,513		$	4,484		$	79,828		$	9,375

Basic earnings per common share	$	0.56		$	0.03		$	0.59		$	0.07
Diluted earnings per common share	$	0.56		$	0.03		$	0.59		$	0.07

Weighted average common shares outstanding - basic	133,634			127,449			133,335			125,799
Weighted average common shares outstanding - diluted	133,696			127,525			133,420			125,889
Dividends declared, per common share, during the period	$	0.30		$	0.30		$	0.60		$	0.60

Table of Contents

Healthcare Realty Trust Incorporated

Condensed Consolidated Statements of Comprehensive Income (Loss)

For the Three and Six Months Ended June 30, 2020 and 2019

Amounts in thousands

Unaudited



	THREE MONTHS ENDED June 30,						SIX MONTHS ENDED June 30,
	2020			2019			2020			2019
Net income	$	75,513		$	4,484		$	79,828		$	9,375
Other comprehensive income (loss)
Interest rate swaps
Reclassification adjustments for losses included in net income (interest expense)	938			( 1		)	1,267			15
Losses arising during the period on interest rate swaps	( 1,455		)	( 4,577		)	( 11,119		)	( 5,301		)
Losses on settlement of treasury rate locks arising during the period	—			—			( 4,267		)	—
	( 517		)	( 4,578		)	( 14,119		)	( 5,286		)
Comprehensive income (loss)	$	74,996		$	( 94	)	$	65,709		$	4,089

Table of Contents

Healthcare Realty Trust Incorporated

Condensed Consolidated Statements of Equity

For the Three Months Ended June 30, 2020 and 2019

Amounts in thousands, except per share data

Unaudited



	Common Stock		Additional Paid-In Capital		Accumulated Other Comprehensive Income (Loss)			Cumulative Net Income		Cumulative Dividends			Total Stockholders’ Equity
Balance at March 31, 2020	$	1,349	$	3,494,123	$	( 19,777	)	$	1,131,619	$	( 2,747,886	)	$	1,859,428
Issuance of common stock, net of issuance costs	11		33,031		—			—		—			33,042
Share-based compensation	—		2,405		—			—		—			2,405
Net income	—		—		—			75,513		—			75,513
Reclassification adjustments for losses included in net income (interest expense)	—		—		938			—		—			938
Losses arising during the period on interest rate swaps	—		—		( 1,455		)	—		—			( 1,455		)
Dividends to common stockholders ($0.30 per share)	—		—		—			—		( 40,510		)	( 40,510		)
Balance at June 30, 2020	$	1,360	$	3,529,559	$	( 20,294	)	$	1,207,132	$	( 2,788,396	)	$	1,929,361

	Common Stock		Additional Paid-In Capital		Accumulated Other Comprehensive Income (Loss)			Cumulative Net Income		Cumulative Dividends			Total Stockholders’ Equity
Balance at March 31, 2019	$	1,292	$	3,302,814	$	( 1,611	)	$	1,093,010	$	( 2,589,726	)	$	1,805,779
Issuance of common stock, net of issuance costs	—		159		—			—		—			159
Share-based compensation	—		2,371		—			—		—			2,371
Net income	—		—		—			4,484		—			4,484
Reclassification adjustments for losses included in net income (interest expense)	—		—		( 1		)	—		—			( 1		)
Losses arising during the period on interest rate swaps	—		—		( 4,577		)	—		—			( 4,577		)
Dividends to common stockholders ($0.30 per share)	—		—		—			—		( 38,771		)	( 38,771		)
Balance at June 30, 2019	$	1,292	$	3,305,344	$	( 6,189	)	$	1,097,494	$	( 2,628,497	)	$	1,769,444

Table of Contents

Healthcare Realty Trust Incorporated

Condensed Consolidated Statements of Equity

For the Six Months Ended June 30, 2020 and 2019

Amounts in thousands, except per share data

Unaudited



	Common Stock		Additional Paid-In Capital			Accumulated Other Comprehensive Income (Loss)			Cumulative Net Income		Cumulative Dividends			Total Stockholders’ Equity
Balance at December 31, 2019	$	1,347	$	3,485,003		$	( 6,175	)	$	1,127,304	$	( 2,707,470	)	$	1,900,009
Issuance of common stock, net of issuance costs	12		40,351			—			—		—			40,363
Common stock redemptions	—		( 798		)	—			—		—			( 798		)
Share-based compensation	1		5,003			—			—		—			5,004
Net income	—		—			—			79,828		—			79,828
Reclassification adjustments for losses included in net income (interest expense)	—		—			1,267			—		—			1,267
Losses arising during the period on interest rate swaps	—		—			( 15,386		)	—		—			( 15,386		)
Dividends to common stockholders ($0.60 per share)	—		—			—			—		( 80,926		)	( 80,926		)
Balance at June 30, 2020	$	1,360	$	3,529,559		$	( 20,294	)	$	1,207,132	$	( 2,788,396	)	$	1,929,361

	Common Stock		Additional Paid-In Capital			Accumulated Other Comprehensive Income (Loss)			Cumulative Net Income		Cumulative Dividends			Total Stockholders’ Equity
Balance at December 31, 2018	$	1,253	$	3,180,284		$	( 902	)	$	1,088,119	$	( 2,552,112	)	$	1,716,642
Issuance of common stock, net of issuance costs	38		120,620			—			—		—			120,658
Common stock redemptions	—		( 570		)	—			—		—			( 570		)
Share-based compensation	1		5,010			—			—		—			5,011
Net income	—		—			—			9,375		—			9,375
Reclassification adjustments for losses included in net income (interest expense)	—		—			14			—		—			14
Losses arising during the period on interest rate swaps	—		—			( 5,301		)	—		—			( 5,301		)
Dividends to common stockholders ($0.60 per share)	—		—			—			—		( 76,385		)	( 76,385		)
Balance at June 30, 2019	$	1,292	$	3,305,344		$	( 6,189	)	$	1,097,494	$	( 2,628,497	)	$	1,769,444

Table of Contents

Healthcare Realty Trust Incorporated

Condensed Consolidated Statements of Cash Flows

For the Six Months Ended June 30, 2020 and 2019

Amounts in thousands

Unaudited



OPERATING ACTIVITIES
	SIX MONTHS ENDED June 30,
	2020			2019
Net income	$	79,828		$	9,375
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	95,188			86,588
Other amortization	2,510			1,547
Share-based compensation	5,004			5,011
Amortization of straight-line rent receivable (lessor)	( 1,807		)	( 1,063		)
Amortization of straight-line rent on operating leases (lessee)	749			776
Gain on sales of real estate assets	( 68,218		)	( 4,865		)
Impairment of real estate assets	—			5,610
Loss from unconsolidated joint ventures	127			3
Distributions from unconsolidated joint ventures	184			277
Changes in operating assets and liabilities:
Other assets, including right-of-use-assets	( 1,272		)	( 2,015		)
Accounts payable and accrued liabilities	( 5,902		)	( 8,621		)
Other liabilities	( 1,152		)	( 1,943		)
Net cash provided by operating activities	105,239			90,680

INVESTING ACTIVITIES
Acquisitions of real estate	( 87,417		)	( 193,295		)
Development of real estate	( 2,678		)	( 13,006		)
Additional long-lived assets	( 44,316		)	( 30,892		)
Proceeds from sales of real estate assets	—			12,118
Net cash used in investing activities	( 134,411		)	( 225,075		)

FINANCING ACTIVITIES
Net (repayments) borrowings on unsecured credit facility	( 293,000		)	58,000
Borrowings on term loan	150,000			50,000
Borrowings of notes and bonds payable	298,995			—
Repayments of notes and bonds payable	( 31,698		)	( 11,483		)
Dividends paid	( 80,926		)	( 76,386		)
Net proceeds from issuance of common stock	40,169			120,668
Common stock redemptions	( 892		)	( 2,442		)
Settlement of treasury rate locks	( 4,267		)	—
Debt issuance and assumption costs	( 3,018		)	( 4,584		)
Payments made on finance leases	( 3,168		)	( 142		)
Net cash provided by financing activities	72,195			133,631

Increase (decrease) in cash and cash equivalents	43,023			( 764		)
Cash and cash equivalents at beginning of period	657			8,381
Cash and cash equivalents at end of period	43,680			$	7,617

Supplemental Cash Flow Information
Interest paid	$	26,101		$	26,512
Invoices accrued for construction, tenant improvements and other capitalized costs	$	10,013		$	10,853
Mortgage notes payable assumed upon acquisition (adjusted to fair value)	$	19,269		$	—
Capitalized interest	$	706		$	651

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1. Summary of Significant Accounting Policies

Business Overview

Healthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of June 30, 2020 , the Company had gross investments of approximately $ 4.2 billion in 210 real estate properties located in 24 states totaling approximately 15.5 million square feet. The Company provided leasing and property management services to approximately 12.0 million square feet nationwide. Square footage and property count disclosures in these Notes to the Company's Condensed Consolidated Financial Statements are unaudited.

Basis of Presentation

The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended December 31, 2019 . All material intercompany transactions and balances have been eliminated in consolidation.

This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 . Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2020 for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties, such as the impact of the COVID-19 pandemic.

Use of Estimates in the Condensed Consolidated Financial Statements

Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.

The Company considered the impact of COVID-19 on these assumptions and estimates used and determined that there were no material adverse impacts on the Company's results of operations and financial position at June 30, 2020. There can be no assurance that COVID-19 will not have a future material adverse impact on the financial results and business operations of the Company.

COVID-19 Update

Since being reported in December 2019, COVID-19 has spread globally, including to every state in the United States. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic, and on March 13, 2020, the United States declared a national emergency with respect to COVID-19.

In response to the COVID-19 pandemic, all of the states and cities in which the Company owns properties, manages properties, and/or has development or redevelopment projects instituted quarantines, restrictions on travel, “shelter in place” rules, restrictions on types of businesses that may continue to operate, and/or restrictions on the types of construction projects that may continue. As a result, a number of the Company's tenants temporarily closed their offices or clinical space or operated on a reduced basis in response to government requirements or recommendations. Many of these restrictions have been lifted, but could be reimposed. In response to these disruptions, the Company provided some of its tenants with deferred rent arrangements. Through July 31, 2020, the Company has collected 97 % of second quarter 2020 aggregate tenant billings and has agreed to various forms of rent deferrals representing approximately 2 % of second quarter 2020 aggregate tenant billings. The tenant deferral agreements require the deferred amounts to be repaid in the third and fourth quarters of 2020.

For accounting purposes, in accordance with ASC 842: Leases, normally a company would be required to assess a lease modification to determine if the modification should be treated as a separate lease and if not, modification

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

accounting would be applied which would require a company to reassess the classification of the lease. However, in light of the COVID-19 pandemic in which many leases are being modified, the Financial Accounting Standards Board (the "FASB") and U.S. Securities and Exchange Commission (the "SEC") have provided relief that will allow companies to make a policy election as to whether they treat COVID-19 related lease amendments as a provision included in the pre-concession arrangement, and therefore, not a lease modification, or to treat the lease amendment as a modification. The Company has elected to use this relief where applicable and therefore will have no change in the current classification of its leases in connection with many of the leases impacted by negotiations with its tenants. In order to be considered COVID-19 related, cash flows must be substantially the same or less than those prior to the concession. If the cash flows are substantially the same or less, there are two methods to potentially account for such rent deferrals under the relief. The first would be as if no changes to the lease contract were made. Under that accounting, a lessor would increase its lease receivable and a lessee would increase its accounts payable as receivables/payments accrue. In its income statement, a lessor would continue to recognize revenue during the deferral period. The second method would be to treat the deferred payments as variable lease payments (i.e., revenue recognized when cash received). The Company has elected the first method described above, which results in the revenue being recognized on an accrual basis.

If tenants are unable to timely repay deferred rent, or repay at all, request additional rent deferrals or abatements, decide not to renew leases, or renew leases at lower cash leasing spreads, the impact on the Company’s results of operations and financial condition could be material. In the second quarter of 2020, the Company recognized approximately $ 0.7 million general reserve against an approximate $ 2.9 million deferred rent balance as of July 17, 2020.

Given the daily evolution of the COVID-19 pandemic and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 pandemic on its results of operations, financial condition, or liquidity for the fiscal year 2020. The Company continues to evaluate the impact of various forms of governmental assistance that may be or become available to the Company or its tenants.

Revenue from Contracts with Customers (Topic 606)

The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance.

Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:



	THREE MONTHS ENDED June 30,				SIX MONTHS ENDED June 30,
in thousands	2020		2019		2020		2019
Type of Revenue
Parking income	$	1,227	$	1,870	$	3,278	$	3,603
Rental lease guaranty	—		—		—		128
Management fee income	69		64		147		133
Miscellaneous	36		32		71		64
	$	1,332	$	1,966	$	3,496	$	3,928

The Company’s major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time, and the Company recognizes revenue monthly based on this principle.

New Accounting Pronouncements

Accounting Standards Update No. 2016-13

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. Operating lease receivables, representing the majority of the Company's receivables, are not within the scope of the new standard. The Company adopted this standard as of January 1, 2020. There was not a material impact to the Condensed Consolidated Financial Statements resulting from the adoption of this standard.

Accounting Standards Update No. 2017-04

In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company adopted this standard as of January 1, 2020. There was not a material impact to the Condensed Consolidated Financial Statements resulting from the adoption of this standard.

Accounting Standards Update No. 2020-04

On March 12, 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848) . ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. The Company has elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur.

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

Note 2. Real Estate Investments

2020 Acquisitions

The following table details the Company's acquisitions for the six months ended June 30, 2020 :



Dollars in millions	TYPE ¹	DATE ACQUIRED	PURCHASE PRICE		MORTGAGE NOTES PAYABLE			CASH CONSIDERATION ²		REAL ESTATE		OTHER ³			SQUARE FOOTAGE
Los Angeles, CA	MOB	1/3/20	$	42.0	$	( 19.3	)	$	22.8	$	42.4	$	( 0.3	)	86,986
Atlanta, GA	MOB	2/13/20	12.0		—			11.8		12.1		( 0.3		)	64,624
Raleigh, NC	MOB	2/25/20	6.3		—			6.5		6.5		—			15,964
Colorado Springs, CO	MOB	3/9/20	8.2		—			8.3		8.6		( 0.3		)	34,210
Denver, CO ⁴	MOB	3/13/20	33.5		—			33.2		34.0		( 0.8		)	136,994
Total real estate acquisitions			$	102.0	$	( 19.3	)	$	82.6	$	103.6	$	( 1.7	)	338,778
Land acquisition ⁵			1.6		—			1.7		1.7		—			—
			$	103.6	$	( 19.3	)	$	84.3	$	105.3	$	( 1.7	)	338,778


1	MOB = medical office building.


2	Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.


3	Includes other assets acquired, liabilities assumed, and intangibles recognized at acquisition.


4	Includes three properties.


5	The Company acquired land parcels under four existing buildings (previously ground leased from the hospital system).

Subsequent Acquisitions

Subsequent to the end of the second quarter of 2020, the Company acquired the following properties:



Dollars in millions	TYPE	DATE ACQUIRED	PURCHASE PRICE		SQUARE FOOTAGE
San Diego, CA	MOB	7/1/20	$	16.7	46,083
Los Angeles, CA	MOB	7/17/20	35.0		49,785
Seattle, WA	MOB	7/23/20	11.0		21,309
Atlanta, GA	MOB	7/31/20	20.5		48,145
Total real estate acquisitions			$	83.2	165,322

Subsequent Dispositions

In May 2020, the Company and Mercy Health negotiated the sale of two single-tenant net leased properties, a medical office building in Oklahoma and an orthopedic specialty hospital in Missouri, for $ 244.5 million . The sale was structured through amendments to the leases to allow for the early exercise of existing purchase options. The amendments resulted in the application of lease modification accounting under ASC Topic 842, which resulted in lease classification changes from operating to sales-type. During the second quarter, the Company derecognized the real estate assets on the Condensed Consolidated Balance Sheets and recognized the net investment in sales-type leases, resulting in a gain of $ 68.3 million . See Note 3 to the Condensed Consolidated Financial Statements for additional disclosures of the sales-type leases. The Company disposed of these properties on July 30, 2020.

Assets Held for Sale

As of June 30, 2020 and December 31, 2019 , the Company had no properties classified as held for sale.

Note 3. Leases

Lessor Accounting

The Company’s properties generally are leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2035. Some leases provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. The Company’s single-tenant net leases generally require the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

The Company's leases typically have escalators that are either based on a stated percentage or an index such as CPI (consumer price index). In addition, most of the Company's leases include nonlease components, such as reimbursement of operating expenses as additional rent, or include the reimbursement of expected operating expenses as part of the lease payment. The Company adopted an accounting policy to combine lease and nonlease components. Rent escalators based on indices and reimbursements of operating expenses that are not included in the lease rate are considered variable lease payments. Variable payments are recognized in the period earned. Lease income for the Company's operating leases recognized for the three and six months ended June 30, 2020 was $ 122.4 million and $ 245.0 million , respectively.

Tabular Disclosure of the Components of Sales-Type Leases

The table below presents the components of sale-type leases for the thee and six months ended June 30, 2020:



	SALES-TYPE LEASES
In thousands	three months ended June 30, 2020		six months ended June 30, 2020
Profit recognized at commencement date	$	68,267	$	68,267	Gain on sales of real estate assets
Interest income	1,553		1,553		Rental income

Future lease payments under the non-cancelable operating and sales-type leases, excluding any reimbursements, as of June 30, 2020 were as follows:



In thousands	Operating		Sales-type ¹
2020	$	181,180	$	249,042
2021	332,072		—
2022	290,524		—
2023	242,546		—
2024	185,184		—
2025 and thereafter	476,791		—
	$	1,708,297	$	249,042


1	See Footnote 2 to the Condensed Consolidated Financial Statements for additional information.

Lessee Accounting

As of June 30, 2020 , the Company was obligated, as the lessee, under operating lease agreements consisting primarily of the Company’s ground leases. As of June 30, 2020 , the Company had 104 properties totaling 8.7 million square feet that were held under ground leases. Some of the ground leases' renewal terms are based on fixed rent renewal terms and others have market rent renewal terms. These ground leases typically have initial terms of 40 to 99 years with expiration dates through 2119 . Any rental increases related to the Company’s ground leases are generally either stated or based on the CPI. The Company had 42 prepaid ground leases as of June 30, 2020 . The amortization of the prepaid rent, included in the operating lease right-of-use asset, represented approximately $ 0.2 million of the Company’s rental expense for the three months ended June 30, 2020 and 2019, respectively and $ 0.3 million for the six months ended June 30, 2020 and 2019, respectively.

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

The Company’s future lease payments (primarily for its 62 non-prepaid ground leases) as of June 30, 2020 were as follows:



In thousands	OPERATING			FINANCING
2020	$	2,012		$	286
2021	4,844			930
2022	4,875			783
2023	4,913			793
2024	4,969			815
2025 and thereafter	307,665			88,808
Total undiscounted lease payments	329,278			92,415
Discount	( 238,019		)	( 73,820		)
Lease liabilities	$	91,259		$	18,595

The following table provides details of the Company's total lease expense for the three and six months ended June 30, 2020 and 2019 :



	THREE MONTHS ENDED June 30,						SIX MONTHS ENDED June 30,
In thousands	2020			2019			2020		2019
Operating lease cost
Operating lease expense	$	1,175		$	1,163		$	2,349	$	2,279
Variable lease expense	804			795			1,604		1,535

Finance lease cost
Amortization of right-of-use assets	78			51			148		51
Interest on lease liabilities	240			196			477		196
Total lease expense	$	2,297		$	2,205		$	4,578	$	4,061

Other information
Operating cash flows outflows related to operating leases	$	1,416		$	1,402		$	3,972	$	4,173
Financing cash flows outflows related to financing leases	$	2,847		$	142		$	3,168	$	142
Right-of-use assets obtained in exchange for new finance lease liabilities	$	7,212		$	—		$	7,212	$	14,294

Weighted-average remaining lease term (excluding renewal options) - operating leases	49.1			49.9
Weighted-average remaining lease term (excluding renewal options) -finance leases	65.0			70.3
Weighted-average discount rate - operating leases	5.7		%	5.5		%
Weighted-average discount rate - finance leases	5.4		%	5.9		%

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

Note 4.

Notes and Bonds Payable

The table below details the Company’s notes and bonds payable.



	MATURITY DATES	BALANCE AS OF				EFFECTIVE INTEREST RATE as of 6/30/2020
Dollars in thousands	MATURITY DATES	6/30/2020		12/31/2019		EFFECTIVE INTEREST RATE as of 6/30/2020
$700 million Unsecured Credit Facility	5/23	$	—	$	293,000	N/A
$200 million Unsecured Term Loan Facility, net of issuance costs ¹	5/24	199,124		199,013		2.00	%
$150 million Unsecured Term Loan due 2026 ²	6/26	149,431		—		3.15	%
Senior Notes due 2023, net of discount and issuance costs	4/23	248,756		248,540		3.95	%
Senior Notes due 2025, net of discount and issuance costs ³	5/25	248,647		248,522		4.08	%
Senior Notes due 2028, net of discount and issuance costs	1/28	295,885		295,651		3.84	%
Senior Notes due 2030, net of discount and issuance costs ⁴	3/30	296,299		—		2.71	%
Mortgage notes payable, net of discounts and issuance costs and including premiums	1/21-4/27	116,794		129,343		4.38	%
		$	1,554,936	$	1,414,069


1	The effective interest rate includes the impact of interest rate swaps on $ 75.0 million at a weighted average rate of 2.37 % (plus the applicable margin rate, currently 100 basis points).


2	The effective interest rate includes the impact of interest rate swaps on $ 100.0 million at a weighted average rate of 2.23 % (plus the applicable margin rate, currently 160 basis points).


3	The effective interest rate includes the impact of the $ 1.7 million settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets.


4	The effective interest rate includes the impact of the $ 4.3 million settlement of forward interest rate hedges that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets.

Changes in Debt Structure

On February 3, 2020 , the Company repaid in full a mortgage note payable bearing interest at a rate of 6.10 % per annum with an outstanding principal of $ 5.9 million . The mortgage note encumbered a 68,860 square foot property in Oklahoma.

On March 4, 2020 , the Company issued $ 300.0 million of unsecured senior notes due 2030 (the "Senior Notes due 2030") in a registered public offering. The Senior Notes due 2030 bear interest at 2.40 % , payable semi-annually on March 15 and September 15 , beginning September 15, 2020, and are due on March 15, 2030, unless redeemed earlier by the Company. The notes were issued at a discount of approximately $ 1.0 million and the Company incurred approximately $ 2.8 million in debt issuance costs. Concurrent with this transaction, the Company settled two treasury rate locks for $ 4.3 million . Inclusive of the discount, debt issuance costs and settlement of the treasury rate locks, the effective interest rate was 2.71 % . The Senior Notes due 2030 have various financial covenants that are required to be met on a quarterly and annual basis.

On May 4, 2020, the Company repaid in full a mortgage note payable bearing interest at a rate of 5.74 % per annum with an outstanding principal of $ 0.3 million . The mortgage note encumbered an 83,318 square foot property in Iowa.

On May 29, 2020, the Company borrowed $ 150.0 million from its unsecured term loan due 2026.

On June 2, 2020, the Company repaid in full a mortgage note payable bearing interest at a rate of 6.44 % per annum with an outstanding principal of $ 12.6 million . The mortgage note encumbered a 67,510 square foot property in Washington.

On June 25, 2020, the Company repaid in full three bonds bearing interest at rates of 5.63 % , 6.63 % and 6.88 % per annum with outstanding principal of $ 0.5 million , $ 2.8 million , and $ 7.0 million , respectively. The bonds encumbered a 60,476 square foot property in Minnesota.

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

Note 5. Derivative Financial Instruments

Risk Management Objective of Using Derivatives

The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk, primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings.

Cash Flow Hedges of Interest Rate Risk

The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. Such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt.

For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in Accumulated Other Comprehensive Income (Loss) ("AOCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in AOCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt.

On February 24 and 25, 2020 , the Company entered into two treasury rate locks totaling $ 75.0 million and $ 40.0 million , respectively. The treasury rate locks were settled for an aggregate amount of $ 4.3 million on March 4, 2020 concurrent with the Company's issuance of its Senior Notes due 2030. The settlement will be amortized over the 10 -year term of the notes.

As of June 30, 2020 , the Company had eight outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:



DERIVATIVE INSTRUMENT	NUMBER OF INSTRUMENTS	NOTIONAL AMOUNT in millions
Interest rate swaps	8	$ 175.0

Tabular Disclosure of Fair Values of Derivative Instruments on the Balance Sheet

The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of June 30, 2020 .



	BALANCE AT JUNE 30, 2020
In thousands	BALANCE SHEET LOCATION	FAIR VALUE
Derivatives designated as hedging instruments
Interest rate swaps	Other liabilities	$	15,339
Total derivatives designated as hedging instruments		$	15,339

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss)

The table below presents the effect of cash flow hedge accounting on AOCI during the three and six months ended June 30, 2020 and 2019 related to the Company's outstanding interest rate swaps.



	LOSS RECOGNIZED IN AOCI ON DERIVATIVE three months ended June 30,					(GAIN) LOSS RECLASSIFIED FROM AOCI INTO INCOME three months ended June 30,
In thousands	2020		2019			2020		2019
Interest rate swaps	$	1,455	$	4,577	Interest expense	$	789	$	( 43	)
Settled treasury hedges	—		—		Interest expense	107		—
Settled interest rate swaps	—		—		Interest expense	42		42
	$	1,455	$	4,577	Total interest expense	$	938	$	( 1	)



	LOSS RECOGNIZED IN AOCI ON DERIVATIVE six months ended June 30,					(GAIN) LOSS RECLASSIFIED FROM AOCI INTO INCOME six months ended June 30,
In thousands	2020		2019			2020		2019
Interest rate swaps	$	11,119	$	5,301	Interest expense	$	1,061	$	( 69	)
Settled treasury hedges	4,267		—		Interest expense	122		—
Settled interest rate swaps	—		—		Interest expense	84		84
	$	15,386	$	5,301	Total interest expense	$	1,267	$	15

The Company estimates that $ 4.4 million will be reclassified from AOCI to interest expense over the next 12 months.

Credit-risk-related Contingent Features

The Company's agreements with each of its derivative counterparties contain a cross-default provision under which the Company could be declared in default of its derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to the Company's default on the indebtedness.

As of June 30, 2020 , the fair value of derivatives in a net liability position including accrued interest but excluding any adjustment for nonperformance risk related to these agreements was $ 16.0 million . As of June 30, 2020 , the Company has not posted any collateral related to these agreements and was not in breach of any agreement.

Note 6. Commitments and Contingencies

Legal Proceedings

The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Redevelopment Activity

The Company initiated the redevelopment of a 110,883 square foot medical office building in Memphis, Tennessee ("Memphis Redevelopment") in December 2019. As of June 30, 2020 , the Company funded approximately $ 2.3 million , excluding the purchase price of $ 8.7 million for the land and building. The building will continue to operate with in-place leases during construction. The Memphis Redevelopment is expected to be completed in the first quarter of 2021.

Development Activity

The Company completed the development of a 151,031 square foot medical office building in Seattle, Washington. As of June 30, 2020 , the Company had funded approximately $ 58.8 million towards the development and additional tenant improvements. The Company expects to fund an additional amount of approximately $ 5.3 million for additional tenant improvements associated with this project. The first tenant took occupancy in the first quarter of 2020.

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

Note 7. Stockholders' Equity

Common Stock

The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the six months ended June 30, 2020 and the year ended December 31, 2019 :



	JUNE 30, 2020	DECEMBER 31, 2019
Balance, beginning of period	134,706,154	125,279,455
Issuance of common stock	1,286,743	9,251,440
Nonvested share-based awards, net of withheld shares	55,274	175,259
Balance, end of period	136,048,171	134,706,154

At-The-Market Equity Offering Program

On February 14, 2020 , the Company entered into sales agreements with six investment banks to allow sales under its at-the-market equity offering program of up to an aggregate of $ 500.0 million of common stock. The Company sold 1,268,237 shares under the Company's at-the market equity offering program during the six months ended June 30, 2020 . The sales generated $ 39.9 million in net proceeds at prices to the public ranging from $ 30.50 to $ 36.15 per share (weighted average of $ 31.86 per share). The sales occurred during the following time periods:


•	During the first quarter of 2020, the Company sold 196,250 shares under the Company's at-the-market equity offering program generating approximately $ 7.0 million in net proceeds at prices to the public ranging from $ 33.00 to $ 36.15 per share (weighted average of $ 36.09 per share).


•	During the second quarter of 2020, the Company sold 1,071,987 shares under the Company's at-the-market equity offering program generating approximately $ 32.9 million in net proceeds at prices to the public ranging from $ 30.50 to $ 31.29 per share (weighted average of $ 31.08 per share).

In addition, the Company entered into two forward equity agreements:


•	In the second quarter of 2020, the Company entered into a forward equity agreement for a total of 1,579,371 shares at an aggregate price of $ 31.66 per share, subject to adjustments as provided in the forward equity agreements. This agreement matures in June 2021.


•	In July 2020, the Company entered into an additional forward equity agreement for a total of 764,472 shares at an aggregate price of $ 31.84 per share, subject to adjustments as provided in the forward equity agreements. This agreement matures in July 2021.

Including the forward equity contracts discussed above, the Company has approximately $ 385.3 million remaining available to be sold under the current sales agreements at the date of this filing.

Common Stock Dividends

During the six months ended June 30, 2020 , the Company declared and paid common stock dividends totaling $ 0.60 per share. On August 4, 2020 , the Company declared a quarterly common stock dividend in the amount of $ 0.30 per share payable on August 31, 2020 to stockholders of record on August 17, 2020 .

Earnings Per Common Share

The Company uses the two-class method of computing net earnings per common shares. The Company's nonvested share-based awards are considered participating securities pursuant to the two-class method.

In June 2020, the Company entered into a forward sale agreement pursuant to a forward equity arrangement to sell approximately 1.6 million shares of common stock through the Company's at-the-market equity offering program.

The Company considered the accounting guidance governing financial instruments and derivatives to account for this agreement and concluded that it was not a liability as it did not embody obligations to repurchase our shares of common stock nor did it embody obligations to issue a variable number of shares for which the monetary value was predominately fixed, varying with something other than the fair value of the shares or varying inversely in relation to the shares. In addition, the Company evaluated whether the agreement met the derivative and hedging guidance

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

scope exception to be accounted for as an equity instrument and concluded that the agreement can be classified as equity.

The Company used the treasury method to determine the dilution from the forward equity agreement during the period of time prior to settlement. The number of weighted-average shares outstanding used in the computation of earnings per common share for the three and six months ended June 30, 2020 , included the effect from the assumed issuance of 1.6 million shares of common stock pursuant to the settlement of the forward equity agreements at the contractual price, less the assumed repurchase of the common stock at the average market price using the proceeds of approximately $ 50.0 million , adjusted for costs to borrow. For the three months ended June 30, 2020 , 11,331 weighted-average incremental shares of common stock were excluded from the computation of weighted-average common shares outstanding - diluted, as the impact was anti-dilutive.

The following table sets forth the computation of basic and diluted earnings per common share for the three and six months ended June 30, 2020 and 2019 .



	THREE MONTHS ENDED JUNE 30,						SIX MONTHS ENDED JUNE 30,
Dollars in thousands, except per share data	2020			2019			2020			2019
Weighted average common shares outstanding
Weighted average common shares outstanding	135,367,081			129,228,102			135,062,708			127,577,389
Non-vested shares	( 1,733,435		)	( 1,778,648		)	( 1,727,762		)	( 1,778,674		)
Weighted average common shares outstanding - basic	133,633,646			127,449,454			133,334,946			125,798,715

Weighted average common shares outstanding - basic	133,633,646			127,449,454			133,334,946			125,798,715
Dilutive effect of forward equity shares	—			—			2,149			—
Dilutive effect of employee stock purchase plan	62,266			75,153			83,217			90,640
Weighted average common shares outstanding - diluted	133,695,912			127,524,607			133,420,312			125,889,355

Net Income	$	75,513		$	4,484		$	79,828		$	9,375
Dividends paid on nonvested share-based awards	( 521		)	( 534		)	( 1,039		)	( 1,070		)
Net income applicable to common stockholders	$	74,992		$	3,950		$	78,789		$	8,305

Basic earnings per common share - net income	$	0.56		$	0.03		$	0.59		$	0.07
Diluted earnings per common share - net income	$	0.56		$	0.03		$	0.59		$	0.07

Incentive Plans

A summary of the activity under the Company's share-based incentive plans for the three and six months ended June 30, 2020 and 2019 is included in the table below.



	THREE MONTHS ENDED JUNE 30,				SIX MONTHS ENDED JUNE 30,
	2020		2019		2020		2019
Share-based awards, beginning of period	1,724,761		1,784,127		1,754,066		1,769,863
Granted	39,493		24,996		78,837		89,767
Vested	( 24,996	)	( 30,989	)	( 93,645	)	( 81,496	)
Share-based awards, end of period	1,739,258		1,778,134		1,739,258		1,778,134

During the six months ended June 30, 2020 and 2019 , the Company withheld 23,563 and 19,546 shares of common stock, respectively, from participants to pay estimated withholding taxes related to shares that vested.

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

In addition to the share-based incentive plans, the Company maintains the 2000 Employee Stock Purchase Plan (the "Purchase Plan"). A summary of the activity under the Purchase Plan for the three and six months ended June 30, 2020 and 2019 is included in the table below.



	THREE MONTHS ENDED JUNE 30,				SIX MONTHS ENDED JUNE 30,
	2020		2019		2020		2019
Outstanding and exercisable, beginning of period	370,696		390,776		332,659		328,533
Granted	—		—		212,716		235,572
Exercised	( 2,463	)	( 4,386	)	( 14,367	)	( 19,016	)
Forfeited	( 6,514	)	( 23,172	)	( 29,495	)	( 39,797	)
Expired	—		—		( 139,794	)	( 142,074	)
Outstanding and exercisable, end of period	361,719		363,218		361,719		363,218

Note 8. Fair Value of Financial Instruments

The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practical to estimate that value.


•	Cash and cash equivalents - The carrying amount approximates fair value due to the short term maturity of these investments.


•	Borrowings under the Unsecured Credit Facility and the Term Loan Due 2024 - The carrying amount approximates fair value because the borrowings are based on variable market interest rates.


•	Senior Notes and Mortgage Notes payable - The fair value of notes and bonds payable is estimated using cash flow analyses, based on the Company’s current interest rates for similar types of borrowing arrangements.


•	Interest rate swap agreements - Interest rate swap agreements are recorded in other liabilities on the Company's Consolidated Balance Sheets at fair value. Fair value is estimated by utilizing pricing models that consider forward yield curves and discount rates.

The table below details the fair values and carrying values for notes and bonds payable at June 30, 2020 and December 31, 2019 .



	JUNE 30, 2020				DECEMBER 31, 2019
Dollars in millions	CARRYING VALUE		FAIR VALUE		CARRYING VALUE		FAIR VALUE
Notes and bonds payable ¹	$	1,554.9	$	1,622.8	$	1,414.1	$	1,425.8


1	Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Disclosure Regarding Forward-Looking Statements

This report and other materials the Company has filed or may file with the Securities and Exchange Commission, as well as information included in oral statements or other written statements made, or to be made, by management of the Company, contain, or will contain, disclosures that are “forward-looking statements.” Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “target,” “intend,” “plan,” “estimate,” “project,” “continue,” “should,” “could," "budget" and other comparable terms. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of risks and uncertainties, including the duration and scope of the COVID-19 pandemic; the impact of the COVID-19 pandemic on occupancy rates for the Company's properties, actions governments take in response to the COVID-19 pandemic, including the introduction of public health measures and other regulations affecting the Company’s properties and the operations of the Company and its tenants; the effects of health and safety measures adopted by the Company and its tenants related to the COVID-19 pandemic; the impact of the COVID-19 pandemic on the operations, business and financial condition of the Company and its tenants; general economic uncertainty in key markets as a result of the COVID-19 pandemic and a worsening of global economic conditions or low levels of economic growth; the status of capital markets, including availability and cost of capital; and the risks described in this report and the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 , that could significantly affect the Company’s current plans and expectations and future financial condition and results.

The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Stockholders and investors are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in the Company’s filings and reports, including, without limitation, estimates and projections regarding the performance of development projects the Company is pursuing.

For a detailed discussion of the Company’s risk factors, please refer to the Company’s filings with the Securities and Exchange Commission, including this report and its Annual Report on Form 10-K for the year ended December 31, 2019 .

COVID-19 Update

In response to the COVID-19 pandemic, all of the states and cities in which the Company owns properties, manages properties, and/or has development or redevelopment projects instituted quarantines, restrictions on travel, “shelter in place” rules, restrictions on types of businesses that may continue to operate, and/or restrictions on the types of construction projects that may continue. As a result, a number of the Company's tenants temporarily closed their offices or clinical space or operated on a reduced basis in response to government requirements or recommendations. Many of these restrictions have been lifted, but could be reimposed. In response to these disruptions, the Company provided some of its tenants with deferred rent arrangements. Through July 31, 2020, the Company has collected 97% of second quarter 2020 aggregate tenant billings and has agreed to various forms of rent deferrals representing approximately 2% of second quarter 2020 aggregate tenant billings. The tenant deferral agreements require the deferred amounts to be repaid in the third and fourth quarters of 2020.

Management believes that many of its tenants who have experienced disruption to their businesses as a result of the COVID-19 pandemic have obtained or will qualify for various forms of government financial assistance including pursuant to the Coronavirus Aid, Relief, and Economic Security Act or the “CARES Act", which was signed into law on March 27, 2020. Accordingly, the Company promotes awareness of the availability of these initiatives to its tenants.

If tenants are unable to timely repay, or repay at all, deferred rent, if they request additional rent deferrals or abatements, decide not to renew leases, or renew leases at lower cash leasing spreads (See “Expiring Leases” below), the impact on the Company’s results of operations and financial condition could be material. In the second quarter of 2020, the Company recognized approximately $0.7 million general reserve against an approximate $2.9 million deferred rent balance as of July 17, 2020.

Table of Contents

At June 30, 2020, the Company had available $743.7 million in liquidity (See “Sources and Uses of Cash” and “Financing Activities” below) and no significant debt maturities prior to 2023. In addition, the Company has entered into forward equity agreements that have expected proceeds of up to approximately $74.3 million that can be settled at the Company's election anytime through July 2021. The COVID-19 pandemic has affected the availability and cost of capital and may continue to do so for some time. Management believes that the Company currently has adequate liquidity to operate its business without significant disruption. However, if the pandemic continues to have an impact on the availability and cost of capital, the Company’s business could be materially affected.

Liquidity and Capital Resources

Sources and Uses of Cash

The Company’s primary sources of cash include rent receipts from its real estate portfolio based on contractual arrangements with its tenants, borrowings under the Company's Unsecured Credit Facility and Term Loan, proceeds from the sales of real estate properties and proceeds from public or private debt or equity offerings. As of June 30, 2020 , the Company had $700.0 million available to be drawn on its Unsecured Credit Facility and $43.7 million in cash. In addition, the Company has entered into forward equity agreements that have expected proceeds of up to approximately $74.3 million that can be settled at the Company's election anytime through June 2021.

The Company expects to continue to meet its liquidity needs, including funding additional investments, paying dividends, and funding debt service, through cash flows from operations and the cash flow sources described above. The Company had unencumbered real estate assets with a gross book value of approximately $3.9 billion at June 30, 2020 , of which a portion could serve as collateral for secured mortgage financing. The Company believes that its liquidity and sources of capital are adequate to satisfy its cash requirements. The Company cannot, however, be certain that these sources of funds will be available at a time and upon terms acceptable to the Company in sufficient amounts to meet its liquidity needs.

Investing Activities

Cash flows used in investing activities for the six months ended June 30, 2020 were approximately $134.4 million . Below is a summary of significant investing activities.

2020 Acquisitions

The following table details the Company's acquisitions for the six months ended June 30, 2020 :



Dollars in millions	HEALTH SYSTEM AFFILIATION	DATE ACQUIRED	PURCHASE PRICE		SQUARE FOOTAGE	CAP RATE		MILES TO CAMPUS
Los Angeles, CA	MemorialCare Health	1/3/20	$	42.0	86,986	5.3	%	0.14
Atlanta, GA	Wellstar Health System	2/13/20	12.0		64,624	5.6	%	0.10
Raleigh, NC	WakeMed Health	2/25/20	6.3		15,964	6.7	%	0.04
Colorado Springs, CO	None	3/9/20	8.2		34,210	6.5	%	1.60
Denver, CO ¹	UCHealth	3/13/20	33.5		136,994	6.1	%	0.24
Total real estate acquisitions			$	102.0	338,778	5.8	%
Land acquisition ²			1.6		—
			$	103.6	338,778


1	Includes three properties.


2	The Company acquired land parcels under four existing buildings (previously ground leased with the hospital system).

Table of Contents

Subsequent Acquisitions

Subsequent to the end of the second quarter of 2020, the Company acquired the following properties:



Dollars in millions	TYPE	DATE ACQUIRED	PURCHASE PRICE		SQUARE FOOTAGE
San Diego, CA	MOB	7/1/20	$	16.7	46,083
Los Angeles, CA	MOB	7/17/20	35.0		49,785
Seattle, WA	MOB	7/23/20	11.0		21,309
Atlanta, GA	MOB	7/31/20	20.5		48,145
Total real estate acquisitions			$	83.2	165,322

Subsequent Dispositions

In May 2020, the Company entered into agreements to sell a medical office building in Oklahoma and an orthopedic specialty hospital in Missouri to Mercy for $244.5 million. See Notes 2 and 3 to the Condensed Consolidated Financial Statements for additional disclosures of the sales-type leases. The Company disposed of these properties on July 30, 2020.

Capital Funding

During the six months ended June 30, 2020 , the Company funded the following:


•	$12.6 million toward development and redevelopment of properties;


•	$7.7 million toward first generation tenant improvements and planned capital expenditures for acquisitions;


•	$12.0 million toward second generation tenant improvements; and


•	$8.2 million toward capital expenditures.

Financing Activities

Cash flows provided by financing activities for the six months ended June 30, 2020 were approximately $72.2 million . Inflows from equity related to the Company's common stock issuances and net borrowings totaled $ 489.2 million , net of issuance costs incurred. Aggregate cash outflows totaled approximately $417.0 million primarily associated with dividends paid to common stockholders and repayments on the Credit Facility. See Notes 4 and 7 to the Condensed Consolidated Financial Statements for more information about capital markets and financing activities.

Common Stock Issuances

On February 14, 2020 , the Company entered into sales agreements with six investment banks to allow sales under its at-the-market equity offering program of up to an aggregate of $500.0 million of common stock. The Company sold 1,268,237 shares under the Company's at-the market equity offering program during the six months ended June 30, 2020 . The sales generated $39.9 million in net proceeds at prices to the public ranging from $30.50 to $36.15 per share (weighted average of $31.86 per share). The sales occurred during the following time periods:


•	During the first quarter of 2020, the Company sold 196,250 shares under the Company's at-the-market equity offering program generating approximately $7.0 million in net proceeds at prices to the public ranging from $33.00 to $36.15 per share (weighted average of $36.09 per share).


•	During the second quarter of 2020, the Company sold 1,071,987 shares under the Company's at-the-market equity offering program generating approximately $32.9 million in net proceeds at prices to the public ranging from $30.50 to $31.29 per share (weighted average of $31.08 per share).

In addition, the Company entered into two forward equity agreements:


•	In the second quarter of 2020, the Company entered into a forward equity agreement for a total of 1,579,371 shares at an aggregate price of $31.66 per share, subject to adjustments as provided in the forward equity agreements. This agreement matures in June 2021.

Table of Contents


•	In July 2020, the Company entered into an additional forward equity agreement for a total of 764,472 shares at an aggregate price of $31.84 per share, subject to adjustments as provided in the forward equity agreements. This agreement matures in July 2021.

Including the forward equity contracts discussed above, the Company has approximately $385.3 million remaining available to be sold under the current sales agreements at the date of this filing.

Debt Activity

On February 3, 2020, the Company repaid in full a mortgage note payable bearing interest at a rate of 6.10% per annum with an outstanding principal of $5.9 million. The mortgage note encumbered a 68,860 square foot property in Oklahoma.

On March 4, 2020, the Company issued $300.0 million of the Senior Notes due 2030 in a registered public offering. The Senior Notes due 2030 bear interest at 2.40%, payable semi-annually on March 15 and September 15, beginning September 15, 2020, and are due on March 15, 2030, unless redeemed earlier by the Company. The notes were issued at a discount of approximately $1.0 million and the Company incurred approximately $2.8 million in debt issuance costs. Concurrent with this transaction, the Company settled two treasury rate locks for $4.3 million. Inclusive of the discount, debt issuance costs and settlement of the treasury rate locks, the effective interest rate was 2.71%. The Senior Notes due 2030 have various financial covenants that are required to be met on a quarterly and annual basis.

On May 4, 2020, the Company repaid in full a mortgage note payable bearing interest at a rate of 5.74% per annum with an outstanding principal of $0.3 million. The mortgage note encumbered a 83,318 square foot property in Iowa.

On May 29, 2020, the Company borrowed $150.0 million from its unsecured term loan due 2026.

On June 2, 2020, the Company repaid in full a mortgage note payable bearing interest at a rate of 6.44% per annum with an outstanding principal of $12.6 million. The mortgage note encumbered a 67,510 square foot property in Washington.

On June 25, 2020, the Company repaid in full three bonds bearing interest at rates of 5.63%, 6.63% and 6.88% per annum with outstanding principal of $0.5 million, $2.8 million, and $7.0 million, respectively. The bonds encumbered a 60,476 square foot property in Minnesota.

The Company has outstanding interest rate derivatives totaling $175.0 million to hedge one-month LIBOR. The following details the amount and rate of each swap (dollars in thousands):



EFFECTIVE DATE	AMOUNT		WEIGHTED AVERAGE RATE		EXPIRATION DATE
December 18, 2017	$	25,000	2.18	%	December 16, 2022
February 1, 2018	50,000		2.46	%	December 16, 2022
May 1, 2019	50,000		2.33	%	May 1, 2026
June 3, 2019	50,000		2.13	%	May 1, 2026
	$	175,000	2.29	%

Operating Activities

Cash flows provided by operating activities increased from $90.7 million for the six months ended June 30, 2019 to $105.2 million for the six months ended June 30, 2020 . Items impacting cash flows from operations include, but are not limited to, cash generated from property operations, interest payments and the timing related to the payment of invoices and other expenses.

The Company may, from time to time, sell properties and redeploy cash from property sales into new investments. To the extent revenues related to the properties being sold exceed income from these new investments, the Company's results of operations and cash flows could be adversely affected.

Table of Contents

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements that are reasonably likely to have a current or future material effect on the Company’s financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

New Accounting Pronouncements

See Note 1 to the Company's Condensed Consolidated Financial Statements accompanying this report for information on new accounting standards.

Trends and Matters Impacting Operating Results

Management monitors factors and trends important to the Company and the REIT industry to gauge the potential impact on the operations of the Company. In addition to the matters discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 , below are some of the factors and trends that management believes may impact future operations of the Company.

COVID-19 Pandemic

For information on the ways that the COVID-19 pandemic is impacting the Company and its tenants, see "COVID-19 Update" above.

Expiring Leases

The Company expects that approximately 15% to 20% of the leases in its multi-tenanted portfolio will expire each year in the ordinary course of business. There are 407 leases totaling 1.6 million square feet in the Company's multi-tenant portfolio that will expire during the remainder of 2020 . Approximately 82% of the leases expiring in 2020 are in buildings located on or adjacent to hospital campuses, are distributed throughout the portfolio, and are not concentrated with any one tenant, health system or market area. The Company typically expects to retain 75% to 90% of multi-tenant property tenants upon expiration, and the retention ratio for the first six months of the year has been within this range.

Included in the 2020 lease expirations is a 111,000 square foot fitness center leased by Baylor Scott & White Health. The fitness center is located in a 217,000 square foot on-campus medical office building. A new operator is expected to execute an approximately 14-year lease for a reconfigured 52,000 square foot fitness center. Baylor will continue to lease and operate the existing fitness center until the construction of the new center is complete. Once the Baylor lease expires, the Company plans a redevelopment of the building including upgrading common areas, bathrooms, and the exterior of the building.

Also included in the 2020 lease expirations is the July 31 expiration of a 62,000 square foot office lease. A telecommunication company occupies three floors of a 145,000 square foot office building and is expected to vacate. The Company has begun marketing the space and anticipates that releasing efforts will include subdividing the space for multiple users. The Company recognized revenue of approximately $0.4 million related to this lease in the second quarter of 2020.

The Company had one single-tenant net leased, on-campus medical office building with a lease term that expired in the second quarter of 2020. The Company has been in discussions about a long-term lease renewal, but given the COVID-19 pandemic, executed a 6-month extension through December 31, 2020 to allow more time to finalize a long-term lease agreement.

Operating Expenses

The Company has historically experienced increases in property taxes throughout its portfolio as a result of increasing assessments and tax rates levied across the country. The Company continues its efforts to appeal property tax increases and manage the impact of the increases. In addition, the Company has historically incurred variability in portfolio utilities expense based on seasonality, with the first and third quarters usually reflecting greater amounts. The effects of these operating expense increases are mitigated in leases that have provisions for operating expense reimbursement. As of June 30, 2020 , leases for 89% of the Company's multi-tenant leased square footage

Table of Contents

allow for some recovery of operating expenses, with 31% having modified gross lease structures and 58% having net lease structures.

Purchase Options

Information about the Company's unexercised purchase options and the amount and basis for determination of the purchase price is detailed in the table below (dollars in thousands):



	NUMBER OF PROPERTIES		GROSS REAL ESTATE INVESTMENT AS OF JUNE 30, 2020
YEAR EXERCISABLE	MOB	INPATIENT	FAIR MARKET VALUE METHOD ¹		NON FAIR MARKET VALUE METHOD ²		TOTAL
Current ³	3	1	$	96,613	$	—	$	96,613
2021	1	—	—		14,984		14,984
2022	—	—	—		—		—
2023	—	—	—		—		—
2024	—	—	—		—		—
2025	4	—	48,165		19,459		67,624
2026	—	—	—		—		—
2027	—	—	—		—		—
2028	1	—	43,957		—		43,957
2029	1	—	26,494		—		26,494
2030 and thereafter	4	—	100,718		—		100,718
Total	14	1	$	315,947	$	34,443	$	350,390


1	The purchase option price includes a fair market value component that is determined by an appraisal process.


2	Includes properties with stated purchase prices or prices based on fixed capitalization rates.


3	These purchase options have been exercisable for an average of 11.9 years.

Non-GAAP Financial Measures and Key Performance Indicators

Management considers certain non-GAAP financial measures and key performance indicators to be useful supplemental measures of the Company's operating performance. A non-GAAP financial measure is generally defined as one that purports to measure financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable measure determined in accordance with GAAP. Set forth below are descriptions of the non-GAAP financial measures management considers relevant to the Company's business and useful to investors, as well as reconciliations of these measures to the most directly comparable GAAP financial measures.

The non-GAAP financial measures and key performance indicators presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income, as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs. Management believes that in order to facilitate a clear understanding of the Company's historical consolidated operating results, these measures should be examined in conjunction with net income and cash flows from operations as presented in the Condensed Consolidated Financial Statements and other financial data included elsewhere in this Quarterly Report on Form 10-Q.

Funds from Operations ("FFO"), Normalized FFO and Funds Available for Distribution ("FAD")

FFO and FFO per share are operating performance measures adopted by the National Association of Real Estate Investment Trusts (“NAREIT”). NAREIT defines FFO as the most commonly accepted and reported measure of a REIT’s operating performance equal to “net income (computed in accordance with GAAP), excluding gains (or losses) from sales of property, plus depreciation and amortization, impairment, and after adjustments for unconsolidated partnerships and joint ventures.”

Table of Contents

In addition to FFO, the Company presents Normalized FFO and FAD. Normalized FFO is presented by adding to FFO acquisition-related costs, acceleration of debt issuance costs, debt extinguishment costs and other Company-defined normalizing items to evaluate operating performance. FAD is presented by adding to Normalized FFO non-real estate depreciation and amortization, deferred financing fees amortization, stock-based compensation expense and provision for bad debts, net; and subtracting maintenance capital expenditures, including second generation tenant improvements and leasing commissions paid and straight-line rent income, net of expense. The Company's definition of these terms may not be comparable to that of other real estate companies as they may have different methodologies for computing these amounts. Normalized FFO and FAD should not be considered as an alternative to net income as an indicator of the Company's financial performance or to cash flow from operating activities as an indicator of the Company's liquidity. Normalized FFO and FAD should be reviewed in connection with GAAP financial measures.

Management believes FFO, Normalized FFO, FFO per share, Normalized FFO per share and FAD ("Non-GAAP Measures") provide an understanding of the operating performance of the Company’s properties without giving effect to certain significant non-cash items, primarily depreciation and amortization expense. Historical cost accounting for real estate assets in accordance with GAAP assumes that the value of real estate assets diminishes predictably over time. However, real estate values instead have historically risen or fallen with market conditions. The Company believes that by excluding the effect of depreciation, amortization, impairments and gains or losses from sales of real estate, all of which are based on historical costs and which may be of limited relevance in evaluating current performance, Non-GAAP Measures can facilitate comparisons of operating performance between periods. The Company reports Non-GAAP Measures because these measures are observed by management to also be the predominant measures used by the REIT industry and by industry analysts to evaluate REITs. For these reasons, management deems it appropriate to disclose and discuss these Non-GAAP Measures. However, none of these measures represent cash generated from operating activities determined in accordance with GAAP and are not necessarily indicative of cash available to fund cash needs. Further, these measures should not be considered as an alternative to net income as an indicator of the Company’s operating performance or as an alternative to cash flow from operating activities as a measure of liquidity. The table below reconciles net income to FFO, Normalized FFO and FAD for the three and six months ended June 30, 2020 and 2019 .

Table of Contents



	THREE MONTHS ENDED JUNE 30,						SIX MONTHS ENDED JUNE 30,
Amounts in thousands, except per share data	2020			2019			2020			2019
Net income	$	75,513		$	4,484		$	79,828		$	9,375
(Gain) on sales of real estate assets	(68,267		)	(4,849		)	(68,218		)	(4,865		)
Impairment of real estate assets	—			5,610			—			5,610
Real estate depreciation and amortization	48,657			44,682			97,269			88,066
FFO attributable to common stockholders	$	55,903		$	49,927		$	108,879		$	98,186
Acquisition and pursuit costs ¹	431			422			1,181			726
Lease intangible amortization	(16		)	54			729			138
Debt financing costs	—			760			—			760
Normalized FFO attributable to common stockholders	$	56,318		$	51,163		$	110,789		$	99,810
Non-real estate depreciation and amortization	822			829			1,645			1,592
Non-cash interest expense amortization ²	1,035			707			1,781			1,409
Provision for bad debt, net	945			150			862			75
Straight-line rent, net	(382		)	(1		)	(1,042		)	(271		)
Stock-based compensation	2,405			2,372			5,003			5,011
Normalized FFO adjusted for non-cash items	$	61,143		$	55,220		$	119,038		$	107,626
2nd generation TI	(6,005		)	(6,124		)	(12,045		)	(10,450		)
Leasing commissions paid	(2,258		)	(2,315		)	(5,082		)	(3,662		)
Capital additions	(4,777		)	(4,993		)	(8,247		)	(8,455		)
FAD	$	48,103		$	41,788		$	93,664		$	85,059
FFO per common share - diluted	$	0.42		$	0.39		$	0.81		$	0.78
Normalized FFO per common share - diluted	$	0.42		$	0.40		$	0.83		$	0.79
FFO weighted average common shares outstanding - diluted ³	134,464			128,279			134,221			126,615


1	Acquisition and pursuit costs include third party and travel costs related to the pursuit of acquisitions and developments.


2	Includes the amortization of deferred financing costs, discounts and premiums.


3	The Company utilizes the treasury stock method which includes the dilutive effect of nonvested share-based awards outstanding of 767,760 and 800,255, respectively for the three and six months ended June 30, 2020.

Cash NOI and Same Store Cash NOI

Cash NOI and Same Store Cash NOI are key performance indicators. Management considers these to be supplemental measures that allow investors, analysts and Company management to measure unlevered property-level operating results. The Company defines Cash NOI as rental income and property lease guaranty income less property operating expenses. Cash NOI excludes non-cash items such as above and below market lease intangibles, straight-line rent, lease inducements, tenant improvement amortization and leasing commission amortization. The Company also excludes cash lease termination fees. Cash NOI is historical and not necessarily indicative of future results.

Same Store Cash NOI compares Cash NOI for stabilized properties. Stabilized properties are properties that have been included in operations for the duration of the year-over-year comparison period presented and include redevelopment projects. Accordingly, stabilized properties exclude properties that were recently acquired or disposed of, properties classified as held for sale, reposition properties and newly developed properties. The Company utilizes the reposition classification for properties experiencing a shift in strategic direction. Such a shift can occur for a variety of reasons, including a substantial change in the use of the asset, a change in strategy or closure of a neighboring hospital, or significant property damage. Such properties may require enhanced management, leasing, capital needs or a disposition strategy that differs from the rest of the portfolio. To identify properties exhibiting these reposition characteristics, the Company applies the following Company-defined criteria:


•	Properties having less than 60% occupancy that is expected to last at least two quarters;


•	Properties that experience a loss of occupancy over 30% in a single quarter; or


•	Properties with negative net operating income that is expected to last at least two quarters.

Table of Contents

Any recently acquired property will be included in the same store pool once the Company has owned the property for eight full quarters. Newly developed properties will be included in the same store pool eight full quarters after substantial completion. Any additional square footage created by redevelopment projects at a same store property is included in the same store pool immediately upon completion. Any property included in the reposition property group will be included in the same store analysis once occupancy has increased to 60% or greater with positive net operating income and has remained at that level for eight full quarters. The following table reflects the Company's same store cash NOI for the three months ended June 30, 2020 and 2019.



	NUMBER OF PROPERTIES	GROSS INVESTMENT at June 30, 2020		SAME STORE CASH NOI for the three months ended June 30,
Dollars in thousands	NUMBER OF PROPERTIES	GROSS INVESTMENT at June 30, 2020		2020		2019
Multi-tenant properties	161	$	3,314,437	$	58,998	$	58,258
Single-tenant net lease properties	12	256,795		5,799		5,887
Total	173	$	3,571,232	$	64,797	$	64,145

The following tables reconcile net income to same store NOI and the same store property metrics to the total owned real estate portfolio for the three months ended June 30, 2020 and 2019 :

Reconciliation of Same Store Cash NOI



	THREE MONTHS ENDED JUNE 30,
Dollars in thousands	2020			2019
Net income	$	75,513		$	4,484
Other income (expense)	(53,959		)	15,354
General and administrative expense	7,434			7,845
Depreciation and amortization expense	47,691			43,926
Other expenses ¹	2,185			1,965
Straight-line rent revenue	(390		)	(8		)
Other revenue ²	(3,213		)	(1,447		)
Cash NOI	75,261			72,119
Cash NOI not included in same store	(10,464		)	(7,974		)
Same store cash NOI	64,797			64,145
Reposition NOI	374			550
Same store and reposition cash NOI	$	65,171		$	64,695


1	Includes acquisition and pursuit costs, bad debt, above and below market ground lease intangible amortization, leasing commission amortization and ground lease straight-line rent expense.


2	Includes management fee income, interest, above and below market lease intangible amortization, lease inducement amortization, lease terminations and tenant improvement overage amortization.

Reconciliation of Same Store Properties



	AS OF JUNE 30, 2020
	PROPERTY COUNT	GROSS INVESTMENT		SQUARE FEET	OCCUPANCY
Same store properties	173	$	3,571,232	13,330,771	88.4	%
Acquisitions	26	535,170		1,455,265	89.2	%
Development completions	1	51,677		151,031	60.5	%
Reposition	10	85,991		523,159	46.9	%
Total owned real estate properties	210	$	4,244,070	15,460,226	86.8	%

Results of Operations

Three Months Ended June 30, 2020 Compared to Three Months Ended June 30, 2019

The Company’s results of operations for the three months ended June 30, 2020 compared to the same period in 2019 were impacted by acquisitions, developments, dispositions, gains on sale, and capital markets transactions.

Table of Contents

Revenues

Total revenues increased $7.4 million , or 6.3% , to approximately $123.7 million for the three months ended June 30, 2020 compared to $116.3 million in the prior year period. This increase is comprised of the following:



	THREE MONTHS ENDED JUNE 30,				CHANGE
Dollars in thousands	2020		2019		$			%
Property operating	$	111,076	$	102,818	$	8,258		8.0	%
Single-tenant net lease	10,518		11,138		(620		)	(5.6	)%
Straight-line rent	764		395		369			93.4	%
Rental income	122,358		114,351		8,007			7.0	%
Other operating	1,332		1,966		(634		)	(32.2	)%
Total revenues	$	123,690	$	116,317	$	7,373		6.3	%

Property operating revenue increased $8.3 million , or 8.0% , from the prior year period primarily as a result of the following activity:


•	Acquisitions in 2019 and 2020 and a development in 2020 contributed $8.4 million.


•	Leasing activity, including contractual rent increases, contributed $0.5 million.


•	Dispositions in 2019 resulted in a decrease of $0.6 million.

Single-tenant net lease revenue decreased $0.6 million , or 5.6% , from the prior year period primarily as a result of the following activity:


•	Dispositions in 2019 resulted in a decrease of $0.8 million.


•	Leasing activity contributed $0.2 million.

Straight-line rent revenue increased $0.4 million or 93.4% from the prior year primarily as a result of the following activity:


•	Acquisitions in 2019 and 2020 and a development in 2020 contributed $0.4 million.


•	Leasing, including contractual rent increases, contributed $0.1 million.


•	Dispositions in 2019 resulted in a decrease of $0.1 million.

Other operating income decreased $0.6 million or 32.2% from the prior year primarily due to a reduction in variable parking revenue.

Expenses

Property operating expenses increased $2.3 million , or 5.2% , for the three months ended June 30, 2020 compared to the prior year period primarily as a result of the following activity:


•	Acquisitions in 2019 and 2020 and a development in 2020 resulted in an increase of $3.6 million.


•	Increases in portfolio operating expenses as follows:


•	Portfolio property tax expense of $0.2 million;


•	Compensation related expenses of $0.2 million; and


•	Portfolio insurance expense of $0.2 million.


•	Maintenance and repair expense decreased $0.6 million.


•	Utilities expense decreased $0.6 million.


•	Administrative and legal fees decreased approximately $0.1 million.


•	Dispositions in 2019 resulted in a decrease of $0.6 million.

General and administrative expenses decreased approximately $0.4 million , or 5.2% , for the three months ended June 30, 2020 compared to the prior year period primarily due as a result of the following activity:

Table of Contents


•	Decrease in compensation expense of approximately $0.2 million.


•	Decrease in travel expense of $0.2 million.

Depreciation and amortization expense increased $3.8 million , or 8.6% , for the three months ended June 30, 2020 compared to the prior year period primarily as a result of the following activity:


•	Acquisitions in 2019 and 2020 and a development in 2020 resulted in an increase of $4.9 million.


•	Various building and tenant improvement expenditures resulted in an increase of $2.6 million.


•	Dispositions in 2019 resulted in a decrease of $0.7 million.


•	Assets that became fully depreciated resulted in a decrease of $3.0 million.

Other income (Expense)

Other income (expense) increased $69.3 million from the prior year mainly due to the following activity:

Gains on sale of real estate properties

Gains on sale of real estate properties totaling approximately $68.3 million and $4.8 million are associated with the two and four real estate properties during 2020 and 2019, respectively. The gain that was recognized in 2020 relates to the agreements to sell two properties which resulted in lease modifications requiring the Company to recognize the gain prior to sale. See Notes 2 and 3 to the Condensed Consolidated Financial Statements for additional disclosures of the sales-type leases.

Interest expense

Interest expense increased $0.6 million , or 4.3% , for the three months ended June 30, 2020 compared to the prior year period. The components of interest expense are as follows:



	THREE MONTHS ENDED JUNE 30,						CHANGE
Dollars in thousands	2020			2019			$		%
Contractual interest	$	13,453		$	13,292		$	161	1.2	%
Net discount/premium accretion	204			51			153		300.0	%
Deferred financing costs amortization	682			613			69		11.3	%
Interest rate swap amortization	42			42			—		—	%
Treasury hedge amortization	107			—			107		—	%
Interest cost capitalization	(286		)	(344		)	58		(16.9	)%
Right-of-use assets financing amortization	240			196			44		22.4	%
Total interest expense	$	14,442		$	13,850		$	592	4.3	%

Contractual interest expense increased $0.2 million , or 1.2% , primarily due to the following activity:


•	The Senior Notes due 2030 accounted for an increase of $1.8 million.


•	The Term Loan due 2024 and the initial funding of the Term Loan due 2026, net of swaps, accounted for an increase of approximately $0.4 million.


•	The Unsecured Credit Facility principal and rate decreases accounted for a decrease of approximately $2.0 million.

Impairment of real estate assets

Impairment of real estate assets totaling approximately $5.6 million is associated with the sales of two real estate properties during 2019.

Interest and other income (expense)

In 2019, the Company expensed approximately $0.8 million of debt issuance costs as a result of the Term Loan modification.

Table of Contents

Six Months Ended June 30, 2020 Compared to Six Months Ended June 30, 2019

The Company’s results of operations for the six months ended June 30, 2020 compared to the same period in 2019 were impacted by acquisitions, developments, dispositions, gains on sale, and capital markets transactions.

Revenues

Total revenues increased $19.5 million , or 8.5% , to approximately $248.5 million for the six months ended June 30, 2020 compared to $229.0 million in the prior year period. This increase is comprised of the following:



	SIX MONTHS ENDED JUNE 30,				CHANGE
Dollars in thousands	2020		2019		$			%
Property operating	$	222,223	$	201,799	$	20,424		10.1	%
Single-tenant net lease	20,971		22,184		(1,213		)	(5.5	)%
Straight-line rent	1,807		1,063		744			70.0	%
Rental income	245,001		225,046		19,955			8.9	%
Other operating	3,496		3,928		(432		)	(11.0	)%
Total revenues	$	248,497	$	228,974	$	19,523		8.5	%

Property operating revenue increased $20.4 million , or 10.1% , from the prior year period primarily as a result of the following activity:


•	Acquisitions in 2019 and 2020 and a development in 2020 contributed $17.9 million.


•	Leasing activity, including contractual rent increases, contributed $4.1 million.


•	Dispositions in 2019 resulted in a decrease of $1.6 million.

Single-tenant net lease revenue decreased $1.2 million , or 5.5% , from the prior year period primarily as a result of the following activity:


•	Dispositions in 2019 resulted in a decrease of $1.5 million.


•	Leasing activity, including contractual increases, contributed $0.3 million.

Straight-line rent revenue increased $0.7 million or 70.0% from the prior year primarily due to acquisitions in 2019 and 2020 and a development in 2020 totaling $0.9 million, partially offset by leasing activity and contractual rent increases totaling $0.2 million.

Other operating income decreased $0.4 million or 11.0% from the prior year primarily due to a reduction in variable parking revenue.

Expenses

Property operating expenses increased $9.1 million , or 10.5% , for the six months ended June 30, 2020 compared to the prior year period primarily as a result of the following activity:


•	Acquisitions in 2019 and 2020 and a development in 2020 resulted in an increase of $7.8 million.


•	Increases in portfolio operating expenses as follows:


•	Portfolio property tax expense of $1.4 million;


•	Compensation related expenses of $0.3 million;


•	Portfolio insurance expense of $0.4 million;


•	Portfolio security expense of $0.3 million; and


•	Portfolio janitorial expense of $0.1 million.


•	Utilities expense resulted in a decrease of $0.7 million.


•	Administrative and legal fees increased approximately $0.2 million.


•	Maintenance and repair expense resulted in a decrease of $0.2 million.


•	Increase in intangible amortization expense totaling $0.7 million.

Table of Contents


•	Dispositions in 2019 resulted in a decrease of $1.2 million.

General and administrative expenses decreased approximately $0.2 million , or 1.0% , for the six months ended June 30, 2020 compared to the prior year period primarily due to travel expense.

Depreciation and amortization expense increased $8.6 million , or 9.9% , for the six months ended June 30, 2020 compared to the prior year period primarily as a result of the following activity:


•	Acquisitions in 2019 and 2020 and a development in 2020 resulted in an increase of $11.0 million.


•	Various building and tenant improvement expenditures resulted in an increase of $5.3 million.


•	Dispositions in 2019 resulted in a decrease of $2.2 million.


•	Assets that became fully depreciated resulted in a decrease of $5.5 million.

Other income (expense)

Other income (expense) increased $69.0 million from the prior year mainly due to the following activity:

Gains on sale of real estate properties

Gains on sale of real estate properties totaling approximately $68.2 million and $4.9 million are associated with the two and four real estate properties during 2020 and 2019, respectively. The gain that was recognized in 2020 relates to the agreements to sell two properties which resulted in lease modifications requiring the Company to recognize the gain prior to sale. See Notes 2 and 3 to the Condensed Consolidated Financial Statements for additional disclosures of the sales-type leases.

Interest expense

Interest expense increased $1.0 million , or 3.5% , for the six months ended June 30, 2020 compared to the prior year period. The components of interest expense are as follows:



	SIX MONTHS ENDED JUNE 30,						CHANGE
Dollars in thousands	2020			2019			$			%
Contractual interest	$	26,850		$	26,485		$	365		1.4	%
Net discount/premium accretion	256			102			154			151.0	%
Deferred financing costs amortization	1,319			1,222			97			7.9	%
Interest rate swap amortization	84			84			—			—	%
Treasury hedge amortization	122			—			122			—	%
Interest cost capitalization	(706		)	(651		)	(55		)	8.4	%
Right-of-use assets financing amortization	477			196			281			143.4	%
Total interest expense	$	28,402		$	27,438		$	964		3.5	%

Contractual interest expense increased $0.4 million , or 1.4% , primarily due to the following activity:


•	Senior Notes due 2030 accounted for an increase of approximately $2.1 million.


•	The Term Loan due 2024 and the initial funding of the Term Loan due 2026, net of swaps, accounted for an increase of approximately $0.8 million.


•	The Unsecured Credit Facility principal and rate decrease accounted for a decrease of approximately $2.4 million.


•	Mortgage notes repayments accounted for a decrease of $0.1 million.

Impairment of real estate assets

Impairment of real estate assets totaling approximately $5.6 million is associated with the sales of two real estate properties during 2019.

Interest and other income (expense)

In 2019, the Company expensed approximately $0.8 million of debt issuance costs as a result of the Term Loan modification.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures about Market Risk

The Company is exposed to market risk in the form of changing interest rates on its debt and mortgage notes. Management uses regular monitoring of market conditions and analysis techniques to manage this risk. During the six months ended June 30, 2020 , there were no material changes in the quantitative and qualitative disclosures about market risks presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 .

Item 4. Controls and Procedures

Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), as of the end of the period covered by this report. Based on this evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by the Company in the reports it files or submits under the Exchange Act.

Changes in Internal Control over Financial Reporting

There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

Item 1A. Risk Factors

In addition to the other information set forth in this report, an investor should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 , and the Company's quarterly report on the Form 10-Q for the quarter ended March 31, 2020 which could materially affect the Company’s business, financial condition or future results. The risks, as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 , and the Company's quarterly report on the Form 10-Q for the quarter ended March 31, 2020 are not the only risks facing the Company. Additional risks and uncertainties not currently known to management or that management currently deems immaterial also may materially, adversely affect the Company’s business, financial condition, operating results or cash flows.

The ongoing COVID-19 pandemic and measures intended to prevent its spread could have a material adverse effect on the Company's business, results of operations, cash flows and financial condition.

The COVID-19 pandemic has had, and another pandemic in the future could have, repercussions across regional and global economies and financial markets. The outbreak of COVID-19 in many countries has significantly adversely impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets. The global impact of the outbreak has been rapidly evolving and many countries, including the United States, have reacted by instituting quarantines, mandating business and school closures and restricting travel.

All of the states and cities in which the Company owns properties, manages properties, and/or has development or redevelopment projects instituted quarantines, restrictions on travel, “shelter in place” rules, restrictions on types of businesses that may continue to operate, and/or restrictions on the types of construction projects that may continue. As a result, a number of the Company's tenants temporarily closed their offices or clinical space or operated on a reduced basis in response to government requirements or recommendations. Many of these restrictions were lifted during the second quarter of 2020, but could be reimposed.

Through July 31, 2020, the Company has collected 97% of second quarter 2020 aggregate tenant billings and has agreed to various forms of rent deferrals representing approximately 2% of second quarter 2020 aggregate tenant billings. The tenant deferral agreements require the deferred amounts to be repaid in the third and fourth quarters of 2020. The tenant deferral agreements require the amounts to be repaid in the third and fourth quarters of 2020.

The COVID-19 pandemic has also caused, and is likely to continue to cause, severe economic, market and other disruptions worldwide. There can be no assurance that conditions in the bank lending, capital and other financial markets will not continue to deteriorate as a result of the pandemic, or that the Company's access to capital and other sources of funding will not become constrained, which could adversely affect the availability and terms of future borrowings, renewals or refinancings. In addition, the deterioration of economic conditions as a result of the pandemic may ultimately decrease occupancy levels and average rent per square foot across the Company's portfolio as tenants reduce or defer their spending.

The extent of the COVID-19 pandemic’s effect on the Company's operational and financial performance will depend on future developments, including the duration, spread and intensity of the outbreak, all of which are uncertain and difficult to predict. Due to the speed with which the situation is developing, the Company is not able at this time to estimate the effect of these factors on its business, but the adverse impact on the business, results of operations, financial condition and cash flows could be material. Moreover, many risk factors set forth in our Annual Report on

Table of Contents

Form 10-K for the year ended December 31, 2019 should be interpreted as heightened risks as a result of the impact of the COVID-19 pandemic.

Settlement provisions contained in a forward equity agreement could result in substantial dilution to the Company's earnings per share and return on equity or result in substantial cash payment obligations.

The Company has outstanding forward equity agreements and may enter into additional forward equity agreements in the future. Forward equity agreements typically provide that the relevant forward purchaser will have the right to accelerate that particular forward equity agreement (with respect to all or any portion of the transaction under that particular forward equity agreement that the relevant forward purchaser determines is affected by such event) and require us to settle on a date specified by the relevant forward purchaser if:


•	the relevant forward purchaser is unable to establish, maintain or unwind its hedge position with respect to that particular forward equity agreement;


•	a termination event occurs as a result of us declaring a dividend or distribution on our common stock with a cash value in excess of a specified amount per calendar quarter, or with an ex-dividend date prior to the anticipated ex-dividend date for such cash dividend;


•	an extraordinary event (as such term is defined in that particular forward equity agreement and which includes certain mergers and tender offers and the delisting of our common stock) occurs or our board of directors votes to approve or there is a public announcement of, in either case, any action that, if consummated, would constitute such an extraordinary event; or


•	certain other events of default, termination events, or other specified events occur, including, among other things, any material misrepresentation made by us in connection with entering into that particular forward equity agreement, or a nationalization, a bankruptcy termination event or a change in law (as such terms are defined in that particular forward equity agreement).

A forward purchaser’s decision to exercise its right to accelerate the settlement of a particular forward equity agreement will be made irrespective of the Company's need for capital. In such cases, we could be required to issue and deliver shares of common stock under the physical settlement provisions of that particular forward equity agreement or, if we so elect and the forward purchaser so permits our election, net share settlement provisions of that particular forward equity agreement irrespective of our capital needs, which would result in dilution to our earnings per share and return on equity.

We expect that settlement of any forward equity agreement will generally occur no later than the date specified in the particular forward equity agreement, which will generally be no later than twelve months following the trade date of that forward equity agreement. However, any forward equity agreement may be settled earlier than that specified date in whole or in part at our option. We expect that each forward equity agreement will be physically settled by delivery of shares of common stock unless we elect to cash settle or net share settle a particular forward equity agreement. Upon physical settlement or, if we so elect, net share settlement of a particular forward equity agreement, delivery of shares of common stock in connection with such physical settlement or net share settlement will result in dilution to our earnings per share and return on equity. If we elect cash settlement or net share settlement with respect to all or a portion of the shares of common stock underlying a particular forward equity agreement, we expect that the relevant forward purchaser (or an affiliate thereof) will purchase a number of shares of common stock necessary to satisfy its or its affiliate’s obligation to return the shares of common stock borrowed from third parties in connection with sales of shares of common stock under that forward equity agreement, adjusted in the case of net share settlement by any shares deliverable by or to us under the forward equity agreement. In addition, the purchase of shares of common stock in connection with the relevant forward purchaser or its affiliate unwinding its hedge positions could cause the price of shares of common stock to increase over such time (or prevent a decrease over such time), thereby increasing the amount of cash we would owe to the relevant forward purchaser (or decreasing the amount of cash that the relevant forward purchaser would owe us) upon a cash settlement of the relevant forward equity agreement or, in the event of net share settlement, increasing the number of shares of common stock we would deliver to the relevant forward purchaser (or decreasing the number of shares of common stock that the relevant forward purchaser would deliver to us).

Table of Contents

The forward equity price that we expect to receive upon physical settlement of a particular forward equity agreement will be subject to adjustment on a daily basis based on a floating interest rate factor equal to a specified daily rate less a spread and will be decreased based on amounts related to expected dividends on shares of common stock during the term of the particular forward equity agreement. If the specified daily rate is less than the spread on any day, the interest factor will result in a daily reduction of the applicable forward equity price. If the market value of shares of common stock, determined in accordance with the terms of the relevant forward equity agreement, during the relevant valuation period under the particular forward equity agreement is above the applicable forward equity price, in the case of cash settlement, we would pay the relevant forward purchaser under that particular forward equity agreement an amount in cash equal to the difference or, in the case of net share settlement, we would deliver to the relevant forward purchaser a number of shares of common stock having a value, determined in accordance with the terms of the relevant forward equity agreement, equal to the difference. Thus, we could be responsible for a potentially substantial cash payment in the case of cash settlement of a particular forward equity agreement. If the market value of the Company’s common stock, determined in accordance with the terms of the relevant forward equity agreement, during the relevant valuation period under that particular forward equity agreement is below the applicable forward equity price, in the case of cash settlement, we would be paid the difference in cash by the relevant forward purchaser under that particular forward equity agreement or, in the case of net share settlement, we would receive from the relevant forward purchaser a number of shares of common stock having a value equal to the difference.

The U.S. federal income tax treatment of the cash that we might receive from cash settlement of a forward equity agreement is unclear and could jeopardize the Company's ability to meet the REIT qualification requirements.

In the event that we elect to settle any forward equity agreement for cash and the settlement price is below the applicable forward equity price, we would be entitled to receive a cash payment from the relevant forward purchaser. Under Section 1032 of the Internal Revenue Code of 1986, as amended (the "Code"), generally, no gains and losses are recognized by a corporation in dealing in its own shares, including pursuant to a "securities futures contract" (as defined in the Code, by reference to the Securities Exchange Act of 1934, as amended). Although we believe that any amount received by us in exchange for our stock would qualify for the exemption under Section 1032 of the Code, because it is not entirely clear whether a forward equity agreement qualifies as a "securities futures contract," the U.S. federal income tax treatment of any cash settlement payment we receive is uncertain. In the event that we recognize a significant gain from the cash settlement of a forward equity agreement, we might be unable to satisfy the gross income requirements applicable to REITs under the Code. In that case, we may be able to rely upon the relief provisions under the Code in order to avoid the loss of our REIT status. Even if the relief provisions apply, we will be subject to a 100% tax on the greater of (i) the excess of 75% of our gross income (excluding gross income from prohibited transactions) over the amount of such income attributable to sources that qualify under the 75% test or (ii) the excess of 95% of our gross income (excluding gross income from prohibited transactions) over the amount of such gross income attributable to sources that qualify under the 95% test, multiplied in either case by a fraction intended to reflect our profitability. In the event that these relief provisions were not available, we could lose our REIT status under the Code.

In case of our bankruptcy or insolvency, any forward equity agreements will automatically terminate, and we would not receive the expected proceeds from any forward sale of shares of the Company’s common stock.

If we file for or consent to a proceeding seeking a judgment in bankruptcy or insolvency or any other relief under any bankruptcy or insolvency law or other similar law affecting creditors’ rights, or we or a regulatory authority with jurisdiction over us presents a petition for our winding-up or liquidation, and we consent to such a petition, any forward equity agreements that are then in effect will automatically terminate. If any such forward equity agreement so terminates under these circumstances, we would not be obligated to deliver to the relevant forward purchaser any shares of common stock not previously delivered, and the relevant forward purchaser would be discharged from its obligation to pay the applicable forward equity price per share in respect of any shares of common stock not previously settled under the applicable forward equity agreement. Therefore, to the extent that there are any shares of common stock with respect to which any forward equity agreement has not been settled at the time of the commencement of any such bankruptcy or insolvency proceedings, we would not receive the relevant forward equity price per share in respect of those shares of common stock.

Table of Contents

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Authorized Repurchases of Equity Securities by the Issuer

On May 5, 2020, the Company’s Board of Directors authorized the repurchase of up to $50 million of outstanding shares of the Company’s common stock either in the open market or through privately negotiated transactions, subject to market conditions, regulatory constraints, and other customary conditions. The Company is not obligated under this authorization to repurchase any specific number of shares. This authorization supersedes all previous stock repurchase authorizations. As of the date of this report, the Company has not repurchased any shares of its common stock under this authorization.

Item 6. Exhibits



EXHIBIT	DESCRIPTION
Exhibit 3.1	Second Articles of Amendment and Restatement of the Company, as amended ¹
Exhibit 3.2	Amended and Restated Bylaws of the Company, as amended ¹
Exhibit 4.1	Specimen Stock Certificate ²
Exhibit 4.2	Indenture, dated as of May 15, 2001, by and between the Company and Branch Banking and Trust Company, as trustee (as successor to the trustee named therein) ³
Exhibit 4.3	Fifth Supplemental Indenture, dated March 26, 2013, by and between the Company and Branch Banking and Trust Company, as Trustee (as successor to the trustee named therein) ⁴
Exhibit 4.4	Form of 3.75% Senior Notes due 2023 (set forth in Exhibit B to the Fifth Supplemental Indenture filed as Exhibit 4.3 thereto) ⁴
Exhibit 4.5	Sixth Supplemental Indenture, dated April 24, 2015, by and between the Company and Branch Banking and Trust Company, as Trustee (as successor to the trustee named therein) ⁵
Exhibit 4.6	Form of 3.875% Senior Notes due 2025 (set forth in Exhibit B to the Sixth Supplemental Indenture filed as Exhibit 4.5 thereto) ⁵
Exhibit 4.7	Seventh Supplemental Indenture, dated December 11, 2017, by and between the Company and Branch Banking and Trust Company, as Trustee. ⁸
Exhibit 4.8	Form of 3.625% Senior Note due 2028 (set forth in Exhibit B to the Seventh Supplemental Indenture filed as Exhibit 4.7 hereto). ⁶
Exhibit 4.9	Eighth Supplemental Indenture, dated March 18, 2020, by and between the Company and Branch Banking and Trust Company, as Trustee. ⁷
Exhibit 4.10	Form of 2.400% Senior Note due 2030 (set forth in Exhibit B to the Eighth Supplemental Indenture filed as Exhibit 4.9 hereto).
Exhibit 31.1	Certification of the Chief Executive Officer of Healthcare Realty Trust Incorporated pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
Exhibit 31.2	Certification of the Chief Financial Officer of Healthcare Realty Trust Incorporated pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
Exhibit 32	Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)
Exhibit 101.INS	The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
Exhibit 101.SCH	XBRL Taxonomy Extension Schema Document (furnished electronically herewith)
Exhibit 101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document (furnished electronically herewith)
Exhibit 101.LAB	XBRL Taxonomy Extension Labels Linkbase Document (furnished electronically herewith)
Exhibit 101.DEF	XBRL Taxonomy Extension Definition Linkbase Document (furnished electronically herewith)
Exhibit 101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document (furnished electronically herewith)


1	Filed as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2018 filed February 13, 2019 and hereby incorporated by reference.

Table of Contents


2	Filed as an exhibit to the Company’s Registration Statement on Form S-11 (Registration No. 33-60506) filed April 2, 1993 and hereby incorporated by reference.


3	Filed as an exhibit to the Company's Current Report on Form 8-K filed May 17, 2001 and hereby incorporated by reference.


4	Filed as an exhibit to the Company's Current Report on Form 8-K filed March 26, 2013 and hereby incorporated by reference.


5	Filed as an exhibit to the Company's Current Report on Form 8-K filed April 24, 2015 and hereby incorporated by reference.


6	Filed as an exhibit to the Company’s Current Report on Form 8-K filed December 11, 2017 and hereby incorporated by reference.


7	Filed as an exhibit to the Company's Current Report on Form 8-K filed March 18, 2020 and hereby incorporated by reference.


8	Filed as an exhibit to the Company's Annual Report on Form 10-K filed February 12, 2020 and hereby incorporated by reference.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



	HEALTHCARE REALTY TRUST INCORPORATED

	By:	/s/ J. CHRISTOPHER DOUGLAS
		J. Christopher Douglas
		Executive Vice President and Chief Financial Officer
		August 5, 2020

TABLE OF CONTENTS

Part I - Financial Information Item 1. Financial Statements Note 1. Summary Of Significant Accounting Policies Note 2. Real Estate Investments Note 3. Leases Note 4. Notes and Bonds Payable Note 5. Derivative Financial Instruments Note 6. Commitments and Contingencies Note 7. Stockholders' Equity Note 8. Fair Value Of Financial Instruments Item 2. Management S Discussion and Analysis Of Financial Condition and Results Of Operations Item 3. Quantitative and Qualitative Disclosures About Market Risk Item 4. Controls and Procedures Part II - Other Information Item 1. Legal Proceedings Item 1A. Risk Factors Item 2. Unregistered Sales Of Equity Securities and Use Of Proceeds Item 6. Exhibits

Exhibits

Exhibit 3.1 Second Articles of Amendment and Restatement of the Company, as amended1 Exhibit 3.2 Amended and Restated Bylaws of the Company, as amended1 Exhibit 4.3 Fifth Supplemental Indenture, dated March 26, 2013, by and between the Company and Branch Banking and Trust Company, as Trustee (as successor to the trustee named therein)4 Exhibit 4.4 Form of 3.75% Senior Notes due 2023 (set forth in Exhibit B to the Fifth Supplemental Indenture filed as Exhibit 4.3 thereto)4 Exhibit 4.5 Sixth Supplemental Indenture, dated April 24, 2015, by and between the Company and Branch Banking and Trust Company, as Trustee (as successor to the trustee named therein)5 Exhibit 4.6 Form of 3.875% Senior Notes due 2025 (set forth in Exhibit B to the Sixth Supplemental Indenture filed as Exhibit 4.5 thereto)5 Exhibit 4.7 Seventh Supplemental Indenture, dated December 11, 2017, by and between the Company and Branch Banking and Trust Company, as Trustee.8 Exhibit 4.8 Form of 3.625% Senior Note due 2028 (set forth in Exhibit B to the Seventh Supplemental Indenture filed as Exhibit 4.7 hereto).6 Exhibit 31.1 Certification of the Chief Executive Officer of Healthcare Realty Trust Incorporated pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith) Exhibit31.2 Certification of the Chief Financial Officer of Healthcare Realty Trust Incorporated pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith) Exhibit32 Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)

HR 10-Q Quarter ended June 30, 2020

Exhibits